Daiichi Sankyo Clinical Trials

Clinical trials sponsored by Daiichi Sankyo — phases, conditions and reported results. Data from ClinicalTrials.gov.

• Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Wit
  Phase 3 · Non-small Cell Lung Cancer · Active, not recruiting · Jul 23, 2025
• Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refracto
  Phase 2 · Relapsed/Refractory Peripheral T-Cell Lymphoma · Active, not recruiting · Jul 22, 2024
• HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small
  Phase 2 · Non-Small Cell Lung Cancer Metastatic · Active, not recruiting · Apr 2, 2024
• A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cance
  Phase 1/2 · Carcinoma, Non-Small-Cell Lung · Active, not recruiting · Jun 13, 2025
• A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT
  Phase 3 · Tenosynovial Giant Cell Tumor · Active, not recruiting · Apr 27, 2023
• A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan
  Phase 2 · Tenosynovial Giant Cell Tumor · Completed · Mar 3, 2025
• Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-po
  Phase 3 · Breast Neoplasms · Active, not recruiting · Jun 9, 2026
• A Study of DS-7011a in Patients With Systemic Lupus Erythematosus
  Phase 1/2 · Systemic Lupus Erythematosus · Completed · May 28, 2026
• A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
  Phase 2 · Metastatic Breast Cancer · Completed · May 7, 2026
• A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients Wit
  Phase 1/2 · Netherton Syndrome · Terminated · May 14, 2026
• A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mu
  Phase 2 · HER2-mutant Non-Small Cell Lung Cancer · Active, not recruiting · Dec 4, 2024
• A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Meta
  Phase 3 · Breast Cancer · Active, not recruiting · May 16, 2025
• A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Part
  Phase 3 · Breast Cancer · Active, not recruiting · Feb 4, 2026
• Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TR
  Phase 2 · Non-small Cell Lung Cancer · Completed · Apr 3, 2024
• A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
  Phase 2 · Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast · Active, not recruiting · Feb 15, 2024

Trials by company

PfizerMerck (MSD)RocheNovartisAstraZenecaJohnson & Johnson (Janssen)Bristol Myers SquibbSanofiGSKEli LillyAbbVieAmgenBayerBoehringer IngelheimNovo NordiskTakedaGilead SciencesModernaBioNTechRegeneronVertexBiogenDaiichi SankyoAstellas PharmaEisaiOtsukaServierIncyteCelltrionSamsung BioepisHanmi PharmaceuticalYuhan

All trials